Diabetes drug Avandia should not be kept on the market because of heart risks associated with taking the drug and the drug’s lack of any unique short-term benefits in keeping blood-sugar levels under control for diabetics, announced a federal scientist today.
Glaxo Smith Kline, maker of the Avandia drug disputes these recommendations.
Currently, the FDA is meeting to decide whether Avandia should be completely pulled from the market or restricted. The FDA was alerted to the risks of Avandia by a New England Journal of Medicine study that revealed a 43% higher risk of heart attack of those taking Avandia compared with people taking alternative or no diabetes medication.
Patients who have suffered from heart attacks or heart problems and who have taken Avandia may be able to file a lawsuit for these injuries.
Click here for the full article